Search results
Results From The WOW.Com Content Network
After a dramatic spike in layoffs in 2022 and 2023, a handful of tech companies are trimming staff once again.. Meta cut roughly 5% of its staff this week, letting go of more than 3,000 employees ...
This list is based on the Forbes Global 2000, which ranks the world's 2,000 largest publicly traded companies. The Forbes list takes into account a multitude of factors, including the revenue, net profit, total assets and market value of each company; each factor is given a weighted rank in terms of importance when considering the overall ...
The company expects to be profitable in 2025. [ 2 ] In July 2023 due to a disappointing sales ramp-up of the recently approved sleep drug daridorexant , coupled with disappointing trial results in both clazosentan and lucerestat , Idorsia announced layoffs of up to five hundred staff of its one thousand two hundred total employees, to reduce ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Dec. 2—Pfizer Inc. is starting to roll out the pharmaceutical company's biggest round of layoffs since 2009, and its Groton laboratories are not immune. Of course, New York-based Pfizer these ...
The following table lists the largest mergers and acquisitions in the pharmaceutical and biotechnology industry (those over $10 billion). Transactions are recorded by the highest transaction dollar value (rather than using the inflation adjusted values).
PhRMA: "The administration is using the IRA’s price-setting scheme to drive political headlines," the pharma industry trade group said in a statement, "but patients will be disappointed when ...
In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies. [24] In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion. [25]